Regulatory22 May 2026, 11:54 am

Venus Remedies Gets Saudi FDA Nod for Plerixafor

AI Summary

Venus Remedies Ltd has received marketing authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor, a stem cell mobilization therapy used in autologous transplantation for multiple myeloma and non-Hodgkin lymphoma. This marks the company's first marketing authorization for Plerixafor globally and supports its strategy to focus on higher-value specialty injectables in regulated markets. The Saudi Arabian pharmaceutical market is projected to grow to USD 17.1 billion by 2033.

Key Highlights

Venus Remedies secures first global marketing authorization for Plerixafor from Saudi FDA.
Plerixafor is used in stem cell mobilization for multiple myeloma and non-Hodgkin lymphoma.
The approval aligns with Venus Remedies' focus on specialty injectables in regulated markets.
Saudi Arabia's pharmaceutical market is projected to reach USD 17.1 billion by 2033.
The GCC stem cell therapy market was estimated at USD 1.2 billion in 2024.

View BSE Filing

VENUSREM

Pharmaceuticals

VENUS REMEDIES LTD.

Price Impact